Intracavitary brachytherapy for carcinoma of the esophagus.
Local control of unresectable esophageal carcinomas remains a significant problem in spite of aggressive treatments. External beam radiation therapy, chemotherapy, and combined modality treatment have all been employed with limited success. Here we review the existing literature and our own experience with external beam radiation followed by low-dose-rate or high-dose-rate intracavitary radiation for carcinoma of esophagus. The addition of intracavitary brachytherapy to external beam irradiation is well tolerated, causes no significant toxicity, and improves local control. Low-dose-rate intracavitary boost compared to high-dose-rate intracavitary boost has the advantage of a greater margin of safety, requires a single application, does not require highly sophisticated computerized technology, and is accompanied with fewer high-grade toxicities. Combined modality therapy consisting of concomitant infusional chemotherapy, external beam irradiation, and low-dose-rate intracavitary boost needs to be investigated.
Micaily
B
B
Department of Radiation Oncology, Allegheny University of Health Sciences, Philadelphia, Pennsylvania 19102-1192, USA.
Miyamoto
C T
CT
Freire
J E
JE
Brady
L W
LW
D001918:Brachytherapy / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D002277:Carcinoma / Q000532:radiotherapy*; D002986:Clinical Trials as Topic; D004938:Esophageal Neoplasms / Q000532:radiotherapy*; D006801:Humans; D011829:Radiation Dosage; D015996:Survival Rate; D016896:Treatment Outcome